Atea Enterprise Value vs Average Equity Analysis
AVIR Stock | USD 3.93 0.01 0.25% |
Trend analysis of Atea PharmaceuticalsInc balance sheet accounts such as Other Current Liab of 20.6 M, Total Current Liabilities of 57 M or Total Stockholder Equity of 434.1 M provides information on Atea PharmaceuticalsI's total assets, liabilities, and equity, which is the actual value of Atea PharmaceuticalsInc to its prevalent stockholders. By breaking down trends over time using Atea PharmaceuticalsI balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Atea |
About Atea Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of Atea PharmaceuticalsInc at a specified time, usually calculated after every quarter, six months, or one year. Atea PharmaceuticalsI Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Atea PharmaceuticalsI and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Atea currently owns. An asset can also be divided into two categories, current and non-current.
Atea PharmaceuticalsI Balance Sheet Chart
Atea PharmaceuticalsI Balance Sheet is one of the main financial statements that report all assets, liabilities, and shareholders' equity for the current year. It provides a basis for different types of computing rates of return, such as return on equity (ROE) or return on asset (ROA), as well as shows how Atea PharmaceuticalsInc uses and utilizes its capital. It also shows what exactly a company owns and owes.
At this time, Atea PharmaceuticalsI's Property Plant And Equipment Gross is relatively stable compared to the past year. As of 05/09/2024, Accumulated Other Comprehensive Income is likely to grow to about 217.3 K, while Other Current Liabilities is likely to drop slightly above 20.6 M. Add Fundamental
Total Assets
Total assets refers to the total amount of Atea PharmaceuticalsI assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Atea PharmaceuticalsInc books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.Total Current Liabilities
Total Current Liabilities is an item on Atea PharmaceuticalsI balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Atea PharmaceuticalsInc are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Most indicators from Atea PharmaceuticalsI's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Atea PharmaceuticalsInc current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Atea PharmaceuticalsInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. As of 05/09/2024, Selling General Administrative is likely to drop to about 47.4 K. In addition to that, Tax Provision is likely to drop to about 967.1 K
2021 | 2022 | 2023 | 2024 (projected) | Interest Income | 213K | 11.2M | 29.2M | 30.7M | Net Interest Income | 213K | 11.2M | 29.2M | 30.7M |
Atea PharmaceuticalsI fundamental ratios Correlations
Click cells to compare fundamentals
Atea PharmaceuticalsI Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Atea PharmaceuticalsI fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 22.1M | 863.6M | 772.9M | 666.7M | 595.0M | 541.8M | |
Other Current Liab | 1.9M | 14.4M | 52.3M | 15.2M | 27.4M | 20.6M | |
Total Current Liabilities | 2.4M | 315.8M | 56.9M | 18.5M | 32.4M | 57.0M | |
Total Stockholder Equity | (49.6M) | 547.8M | 710.1M | 640.6M | 555.2M | 434.1M | |
Other Liab | 95K | 36K | 5.9M | 5.3M | 6.0M | 6.3M | |
Net Tangible Assets | (49.6M) | 547.8M | 710.1M | 640.6M | 736.7M | 398.8M | |
Property Plant And Equipment Net | 41K | 48K | 23K | 4.1M | 3.1M | 3.3M | |
Net Debt | (21.7M) | (850.1M) | (764.2M) | (643.6M) | (141.4M) | (148.5M) | |
Retained Earnings | (54.2M) | (65.2M) | 56.0M | (59.9M) | (195.8M) | (186.0M) | |
Accounts Payable | 548K | 60K | 4.5M | 2.6M | 4.3M | 2.3M | |
Cash | 21.7M | 850.1M | 764.4M | 646.7M | 143.8M | 136.6M | |
Cash And Short Term Investments | 21.7M | 850.1M | 764.4M | 646.7M | 578.1M | 530.8M | |
Common Stock Shares Outstanding | 82.6M | 82.4M | 88.2M | 83.2M | 83.4M | 85.7M | |
Liabilities And Stockholders Equity | 22.1M | 863.6M | 772.9M | 666.7M | 595.0M | 541.8M | |
Non Current Liabilities Total | 69.2M | 36K | 5.9M | 7.7M | 7.4M | 7.0M | |
Other Current Assets | 249K | 7.5M | 8.0M | 14.2M | 12.3M | 7.8M | |
Other Stockholder Equity | 4.6M | 612.9M | 654.0M | 701.1M | 750.7M | 500.0M | |
Total Liab | 71.6M | 315.8M | 62.8M | 26.1M | 39.8M | 78.3M | |
Net Invested Capital | (49.6M) | 547.8M | 710.1M | 640.6M | 555.2M | 434.1M | |
Property Plant And Equipment Gross | 41K | 48K | 184K | 4.4M | 3.8M | 4.0M | |
Total Current Assets | 21.9M | 863.5M | 772.4M | 660.9M | 590.5M | 539.7M | |
Accumulated Other Comprehensive Income | (69.1M) | (863.6M) | 0.0 | (684K) | 207K | 217.4K | |
Net Working Capital | 19.5M | 547.7M | 715.5M | 642.4M | 558.1M | 461.3M | |
Property Plant Equipment | 41K | 48K | 23K | 4.1M | 4.7M | 4.9M |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Atea PharmaceuticalsI in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Atea PharmaceuticalsI's short interest history, or implied volatility extrapolated from Atea PharmaceuticalsI options trading.
Pair Trading with Atea PharmaceuticalsI
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Atea PharmaceuticalsI position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Atea PharmaceuticalsI will appreciate offsetting losses from the drop in the long position's value.Moving together with Atea Stock
0.72 | EGRX | Eagle Pharmaceuticals | PairCorr |
0.69 | ELAN | Elanco Animal Health Trending | PairCorr |
The ability to find closely correlated positions to Atea PharmaceuticalsI could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Atea PharmaceuticalsI when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Atea PharmaceuticalsI - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Atea PharmaceuticalsInc to buy it.
The correlation of Atea PharmaceuticalsI is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Atea PharmaceuticalsI moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Atea PharmaceuticalsInc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Atea PharmaceuticalsI can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Atea PharmaceuticalsInc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Complementary Tools for Atea Stock analysis
When running Atea PharmaceuticalsI's price analysis, check to measure Atea PharmaceuticalsI's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atea PharmaceuticalsI is operating at the current time. Most of Atea PharmaceuticalsI's value examination focuses on studying past and present price action to predict the probability of Atea PharmaceuticalsI's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Atea PharmaceuticalsI's price. Additionally, you may evaluate how the addition of Atea PharmaceuticalsI to your portfolios can decrease your overall portfolio volatility.
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |
Is Atea PharmaceuticalsI's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Atea PharmaceuticalsI. If investors know Atea will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Atea PharmaceuticalsI listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 2.641 | Earnings Share (1.63) | Revenue Per Share 2.31 | Quarterly Revenue Growth 2.952 | Return On Assets (0.12) |
The market value of Atea PharmaceuticalsInc is measured differently than its book value, which is the value of Atea that is recorded on the company's balance sheet. Investors also form their own opinion of Atea PharmaceuticalsI's value that differs from its market value or its book value, called intrinsic value, which is Atea PharmaceuticalsI's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Atea PharmaceuticalsI's market value can be influenced by many factors that don't directly affect Atea PharmaceuticalsI's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Atea PharmaceuticalsI's value and its price as these two are different measures arrived at by different means. Investors typically determine if Atea PharmaceuticalsI is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Atea PharmaceuticalsI's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.